Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451630 | 0.81 | HSP90AA1 (0.47) | HSP90AA1HSP90AB1PHGDHSMN1; SMN2RAB9A | |
| SCHEMBL449259 | 0.75 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL449157 | 0.75 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL447103 | 0.74 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL446744 | 0.73 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL448081 | 0.72 | HSP90AA1 (0.50) | HSP90AA1HSP90AB1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL451054 | 0.70 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL464711 | 0.70 | HSP90AA1 (0.70) | HSP90AA1HSP90AB1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL445821 | 0.70 | MAPT (0.48) | HSP90AA1HSP90AB1RAB9ANPC1KMT2A | |
| SCHEMBL2469915 | 0.69 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680100-B2 | Sulfonylhydrazide compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120065206-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065206-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | PKD1, PKD2, PCNA | HSP90AA1 2300/4885HSP90AB1 1711/4885PHGDH 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.